Bayer Plans to Expand Lerma, State of México Plant to Boost Pharmaceutical Output for the Americas

Bayer is moving forward with a projected expansion of its plant in Lerma, State of México, as part of a plan to increase production capacity by 40% and strengthen its manufacturing platform for the Americas.

The company expects to invest over MXN 1 billion billion over the next two years, with the expansion plan aimed at reinforcing the facility’s role in the production of over-the-counter medicines for both the domestic market and export destinations.

Bayer Eyes Greater Production Capacity in Lerma

The planned expansion reflects Bayer’s intention to scale operations at one of its key manufacturing sites in Mexico. The Lerma plant produces a range of consumer health products, including Aspirin, Alka-Seltzer, Flanax, and Redoxon, which continue to represent an important part of the company’s portfolio in the region.

If completed as projected, the additional capacity would allow Bayer to respond more efficiently to demand across multiple markets while strengthening the operational relevance of its Mexican manufacturing base.

Mexico’s Role in Bayer’s Export Strategy

The expansion plan is also tied to Bayer’s export strategy for the Americas. The Lerma operation is expected to support greater supply to markets such as the United States, Canada, and Latin America, positioning Mexico as an important production platform within the company’s regional network.

This approach reflects the growing importance of manufacturing locations that can serve multiple countries with competitive logistics, scale, and supply chain flexibility.

Self-Care Products Remain a Key Growth Segment

Among Bayer’s products in Mexico, the Aspirin and Alka-Seltzer families continue to stand out as major production drivers, both for domestic sales and exports. These products remain central to the company’s consumer health operations and help support its broader presence in the market.

The projected expansion is aligned with Bayer’s interest in addressing demand related to self-care solutions, a segment that continues gaining relevance as healthcare systems and consumers increasingly prioritize accessible treatment options for common conditions.

A Signal of Continued Confidence in Mexico

Although the project remains a plan in progress, the scale of the proposed investment signals continued confidence in Mexico’s manufacturing capabilities and in the strategic value of the Lerma site.

For the pharmaceutical industry, decisions of this kind reflect the importance of having production platforms that can combine quality, efficiency, and regional market reach. If finalized as expected, Bayer’s expansion in Lerma would further reinforce Mexico’s position within the pharmaceutical supply chain for the Americas.